-
Pluslife Wins the "2024 Medical Health Corporate Responsibility Model Award," Leading New Breakthroughs in Tuberculosis Control
Pluslife won the "2024 Medical Health Corporate Responsibility Model Award" at the 14th Philanthropy Festival and 2024 ESG Impact Summit, recognizing its outstanding contributions to global tuberculosis control and corporate social responsibility.
넶0 2025-01-16 -
Pluslife Advances Global TB Testing Innovation and Expands Development of Drug-Resistant TB Products
Pluslife is accelerating efforts to provide cost-effective TB diagnostic tools, enhancing accessibility in high-burden areas, and helping to curb TB's spread globally.
넶0 2024-12-04 -
Advancing TB Diagnostics: Pluslife's Commitment to Accessible Solutions
Pluslife’s TB detection product has surpassed the World Health Organization’s (WHO) stringent requirements for 'near POC non-sputum diagnostic' platforms.
넶122 2024-11-25 -
Pluslife Secures Indonesian Import License for Groundbreaking Mycobacterium Tuberculosis Nucleic Acid Test Card
Recently, Pluslife's self-developed rapid molecular diagnostic test card for tuberculosis, utilizing tongue swab samples, was awarded an import medical device license by the Indonesian government. This milestone marks a significant breakthrough following the earlier certification of Pluslife’s sputum sample TB diagnostic technology.
넶171 2024-09-09 -
Pluslife Biotech Founder, Prof. Songyang Speaks on Next-Generation Molecular POCT Technology at the International Health Industry Forum of Boao Forum for Asia
From April 20th to 21st, the International Health Industry Forum of Boao Forum for Asia was held in Beijing, China. The event brought together decision-makers, healthcare providers, experts, and investors to promote global innovation and development in healthcare. The Founder of Pluslife Biotech, Prof. SONGYANG Zhou spoke on the panel “Diagnostic Companies and How They Engage with Global Public Health” to share ideas on how Next-Generation Molecular POCT
넶98 2024-08-05 -
Pluslife MiniDock Achieves Outstanding Accuracy and Usability in PATH APOLLO Project
In the recent APOLLO evaluation project conducted at the PATH laboratory in Seattle, Pluslife MiniDock has gained satisfactory results in terms of test performance and usability, confirming its testing accuracy and strong usability in LMICs (Low- and Middle-Income Countries).
넶224 2024-08-05
